HMNC Holding GmbH: HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-releas

Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.Potential first-in-class oral prolonged-release formulation of ketamine, KET01,

Related Keywords

Germany ,Australia ,Pratteln ,Switzerland General ,Switzerland ,Munich ,Bayern ,Zurich ,Züsz ,South Africa ,Schopfheim ,Baden Wüberg ,German ,Swiss ,Michael Colla ,Martin Renner ,Anne Donohoe ,Hans Eriksson ,Alexander Schmidt ,Erich Seifritz ,Develco Pharma ,Tim Regan Sophia Bashford ,Kostenloser Wertpapierhandel ,Ketabon Program ,Psychiatric University Hospital Zurich ,Holding Gmb ,University Of Basel ,Brain Health ,Department Of Psychiatry ,University Of Zurich ,Clinical Development ,Depression Rating Scale ,Treatment Resistant Depression ,Clinician Administered Dissociative States Scale ,Chief Clinical Development Officer ,Professor Erich Seifritz ,Psychiatric University Hospital ,Major Depressive Disorder ,Scientific Advisory Board ,Major Depression ,Hmnc ,Molding ,Mbh ,Rain ,Health ,Evelco ,Dharma ,Nnounce ,Romising ,Reliminary ,Results ,Treatment ,Resistant ,Depression ,Asuggesting ,Antidepressant ,Efficacy ,Showing ,Placebo ,Level ,Dissociative ,